BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, Spear KL, Large TH, Campbell UC, Hanania T, Leahy E, Koblan KS. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D 2 Receptor Mechanism of Action. J Pharmacol Exp Ther 2019;371:1-14. [DOI: 10.1124/jpet.119.260281] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Schmack K, Ott T, Kepecs A. Computational Psychiatry Across Species to Study the Biology of Hallucinations. JAMA Psychiatry 2021. [PMID: 34817545 DOI: 10.1001/jamapsychiatry.2021.3200] [Reference Citation Analysis]
2 Chen YL, Shi Y, LaFayette A, Shi L, Koblan KS, Galluppi GR. A sensitive LC-MS/MS method for simultaneous quantification of ulotaront and its N-desmethyl metabolite in human plasma and application to a clinical study. J Pharm Biomed Anal 2022;207:114404. [PMID: 34700199 DOI: 10.1016/j.jpba.2021.114404] [Reference Citation Analysis]
3 Kwan C, Huot P. An overview of the active clinical trials for Parkinson's disease psychosis. Neurodegener Dis Manag 2022. [PMID: 35592949 DOI: 10.2217/nmt-2022-0020] [Reference Citation Analysis]
4 Dorotenko A, Tur M, Dolgorukova A, Bortnikov N, Belozertseva IV, Zvartau EE, Gainetdinov RR, Sukhanov I. The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. Cell Mol Neurobiol 2020;40:215-28. [PMID: 31734895 DOI: 10.1007/s10571-019-00757-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tricklebank MD, Robbins TW, Simmons C, Wong EHF. Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology. Psychopharmacology (Berl) 2021;238:1417-36. [PMID: 33694032 DOI: 10.1007/s00213-021-05787-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Vincent F, Nueda A, Lee J, Schenone M, Prunotto M, Mercola M. Phenotypic drug discovery: recent successes, lessons learned and new directions. Nat Rev Drug Discov. [DOI: 10.1038/s41573-022-00472-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Pahwa M, Sleem A, Elsayed OH, Good ME, El-Mallakh RS. New Antipsychotic Medications in the Last Decade. Curr Psychiatry Rep 2021;23:87. [PMID: 34843030 DOI: 10.1007/s11920-021-01298-w] [Reference Citation Analysis]
8 Nair PC, Chalker JM, Mckinnon RA, Langmead CJ, Gregory KJ, Bastiampillai T. Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.2c00016] [Reference Citation Analysis]
9 Zhu S, Wu M, Huang Z, An J. Trends in application of advancing computational approaches in GPCR ligand discovery. Exp Biol Med (Maywood) 2021;246:1011-24. [PMID: 33641446 DOI: 10.1177/1535370221993422] [Reference Citation Analysis]
10 Wang Y, He Y, Yang F, Abame MA, Wu C, Peng Y, Feng L, Shen J, Wang Z, He L. TPN672: A Novel Serotonin-Dopamine Receptor Modulator for the Treatment of Schizophrenia. J Pharmacol Exp Ther 2021;378:20-30. [PMID: 33975897 DOI: 10.1124/jpet.120.000414] [Reference Citation Analysis]
11 Gomes FV, Grace AA. Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. Int J Mol Sci 2021;22:4467. [PMID: 33922888 DOI: 10.3390/ijms22094467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Alnefeesi Y, Tamura JK, Lui LMW, Jawad MY, Ceban F, Ling S, Nasri F, Rosenblat JD, McIntyre RS. Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. Neurosci Biobehav Rev 2021;131:192-210. [PMID: 34537265 DOI: 10.1016/j.neubiorev.2021.09.020] [Reference Citation Analysis]
13 Spark DL, Fornito A, Langmead CJ, Stewart GD. Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry 2022;12:147. [PMID: 35393394 DOI: 10.1038/s41398-022-01904-2] [Reference Citation Analysis]
14 Geerts H, van der Graaf P. Computational Approaches for Supporting Combination Therapy in the Post-Aducanumab Era in Alzheimer’s Disease. ADR 2021;5:815-26. [DOI: 10.3233/adr-210039] [Reference Citation Analysis]
15 Zhang Y, Li JT, Wang H, Niu WP, Zhang CC, Zhang Y, Wang XD, Si TM, Su YA. Role of trace amine‑associated receptor 1 in the medial prefrontal cortex in chronic social stress-induced cognitive deficits in mice. Pharmacol Res 2021;167:105571. [PMID: 33753244 DOI: 10.1016/j.phrs.2021.105571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Xiao G, Chen YL, Dedic N, Xie L, Koblan KS, Galluppi GR. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia. Pharm Res 2022. [PMID: 35484370 DOI: 10.1007/s11095-022-03267-1] [Reference Citation Analysis]
17 Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig 2021;41:1067-73. [PMID: 34751928 DOI: 10.1007/s40261-021-01094-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Geerts H, Roberts P, Spiros A. Exploring the relation between BOLD fMRI and cognitive performance using a computer-based quantitative systems pharmacology model: Applications to the COMTVAL158MET genotype and ketamine. Eur Neuropsychopharmacol 2021;50:12-22. [PMID: 33951587 DOI: 10.1016/j.euroneuro.2021.04.001] [Reference Citation Analysis]
19 Kantrowitz JT. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions. CNS Drugs 2021;35:1153-61. [PMID: 34655036 DOI: 10.1007/s40263-021-00864-3] [Reference Citation Analysis]
20 Kantrowitz JT. The Potential Role of Lumateperone-Something Borrowed? Something New? JAMA Psychiatry 2020;77:343-4. [PMID: 31913409 DOI: 10.1001/jamapsychiatry.2019.4265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
21 Begni V, Sanson A, Luoni A, Sensini F, Grayson B, Munni S, Neill JC, Riva MA. Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856. Int J Mol Sci 2021;22:4119. [PMID: 33923479 DOI: 10.3390/ijms22084119] [Reference Citation Analysis]
22 Hopkins SC, Ogirala A, Loebel A, Koblan KS. Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM). Psychiatry Res 2020;294:113569. [PMID: 33223272 DOI: 10.1016/j.psychres.2020.113569] [Reference Citation Analysis]
23 Reddy HM, Poole JS, Maguire GA, Stahl SM. New Medications for Neuropsychiatric Disorders. Psychiatr Clin North Am 2020;43:399-413. [PMID: 32439029 DOI: 10.1016/j.psc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Lobo MC, Whitehurst TS, Kaar SJ, Howes OD. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neurosci Biobehav Rev 2021;132:324-61. [PMID: 34838528 DOI: 10.1016/j.neubiorev.2021.11.032] [Reference Citation Analysis]
25 Mantas I, Millan MJ, Di Cara B, Groenink L, Veiga S, Cistarelli L, Brocco M, Bertrand M, Svenningsson P, Zhang X. Trace Amine-Associated Receptor 1 Contributes to Diverse Functional Actions of O-Phenyl-Iodotyramine in Mice but Not to the Effects of Monoamine-Based Antidepressants. Int J Mol Sci 2021;22:8907. [PMID: 34445611 DOI: 10.3390/ijms22168907] [Reference Citation Analysis]
26 Dodd S, F Carvalho A, Puri BK, Maes M, Bortolasci CC, Morris G, Berk M. Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry? Neurosci Biobehav Rev 2021;120:537-41. [PMID: 33031817 DOI: 10.1016/j.neubiorev.2020.09.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 Mantas I, Vallianatou T, Yang Y, Shariatgorji M, Kalomoiri M, Fridjonsdottir E, Millan MJ, Zhang X, Andrén PE, Svenningsson P. TAAR1-Dependent and -Independent Actions of Tyramine in Interaction With Glutamate Underlie Central Effects of Monoamine Oxidase Inhibition. Biol Psychiatry 2021;90:16-27. [PMID: 33579534 DOI: 10.1016/j.biopsych.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Neef J, Palacios DS. Progress in mechanistically novel treatments for schizophrenia. RSC Med Chem 2021;12:1459-75. [PMID: 34671731 DOI: 10.1039/d1md00096a] [Reference Citation Analysis]
29 Galluppi GR, Polhamus DG, Fisher JM, Hopkins SC, Koblan KS. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34292664 DOI: 10.1002/psp4.12692] [Reference Citation Analysis]
30 Stępnicki P, Kondej M, Koszła O, Żuk J, Kaczor AA. Multi-targeted drug design strategies for the treatment of schizophrenia. Expert Opin Drug Discov 2021;16:101-14. [PMID: 32915109 DOI: 10.1080/17460441.2020.1816962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Francesconi V, Cichero E, Kanov EV, Laurini E, Pricl S, Gainetdinov RR, Tonelli M. Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Pharmaceuticals (Basel) 2020;13:E391. [PMID: 33202687 DOI: 10.3390/ph13110391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
32 Kokkinou M, Irvine EE, Bonsall DR, Natesan S, Wells LA, Smith M, Glegola J, Paul EJ, Tossell K, Veronese M, Khadayate S, Dedic N, Hopkins SC, Ungless MA, Withers DJ, Howes OD. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry 2021;26:2562-76. [PMID: 32382134 DOI: 10.1038/s41380-020-0740-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
33 Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, Campbell JE, Dedic N, Hopkins SC, Koblan KS, Xie L. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. ACS Med Chem Lett 2022;13:92-8. [PMID: 35047111 DOI: 10.1021/acsmedchemlett.1c00527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Dedic N, Dworak H, Zeni C, Rutigliano G, Howes OD. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. IJMS 2021;22:13185. [DOI: 10.3390/ijms222413185] [Reference Citation Analysis]
35 Hopkins SC, Dedic N, Koblan KS. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans. Transl Psychiatry 2021;11:228. [PMID: 33879769 DOI: 10.1038/s41398-021-01331-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Radan M, Bošković J, Dobričić V, Čudina O, Nikolić K. Current computer-aided drug design methodologies in discovery of novel drug candidates for neuropsychiatric and inflammatory diseases. Arhiv za farmaciju 2021;71:225-56. [DOI: 10.5937/arhfarm71-32523] [Reference Citation Analysis]
37 Tonelli M, Cichero E. Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present). Expert Opinion on Therapeutic Patents 2020;30:137-45. [DOI: 10.1080/13543776.2020.1708900] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
38 Correll CU, Koblan KS, Hopkins SC, Li Y, Heather Dworak, Goldman R, Loebel A. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr 2021;7:63. [PMID: 34887427 DOI: 10.1038/s41537-021-00190-z] [Reference Citation Analysis]
39 Synan C, Bowen C, Heal DJ, Froger-Colléaux C, Beardsley PM, Dedic N, Hopkins SC, Campbell U, Koblan KS. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats. Drug Alcohol Depend 2021;231:109261. [PMID: 35033729 DOI: 10.1016/j.drugalcdep.2021.109261] [Reference Citation Analysis]
40 Dorfman BJ, Jimenez-Shahed J. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia. Expert Rev Neurother 2021;21:9-20. [PMID: 33174440 DOI: 10.1080/14737175.2021.1848548] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]